

Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline



Authors

C. Hassan¹, M. Bretthauer², M. F. Kaminski³, M. Polkowski³, B. Rembacken⁴, B. Saunders⁵, R. Benamouzig⁶, O. Holme⁷, S. Green², T. Kuiper⁸, R. Marmo⁹, M. Omar¹⁰, L. Petruzzello¹, C. Spada¹, A. Zullo¹¹, J. M. Dumonceau¹²

Institutions

Institutions are listed at the end of article.

Bibliography

DOI <http://dx.doi.org/10.1055/s-0032-1326186>
Published online: 0.0.
Endoscopy 2013; 45: 142–150
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X

Corresponding author

J. M. Dumonceau, MD PhD
HUG – Gastroenterology
Rue Micheli-du-Crest 24
Geneva 1205
Switzerland
Fax: +41-22-3729366
Jean-Marc.Dumonceau@hcuge.ch
jmdumonceau@hotmail.com

Background and aim: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the choice amongst regimens available for cleansing the colon in preparation for colonoscopy.

Methods: This Guideline is based on a targeted literature search to evaluate the evidence supporting the use of bowel preparation for colonoscopy. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was adopted to define the strength of recommendation and the quality of evidence.

Results: The main recommendations are as follows. (1) The ESGE recommends a low-fiber diet on the day preceding colonoscopy (weak recommendation, moderate quality evidence). (2) The ESGE recommends a split regimen of 4L of polyethylene glycol (PEG) solution (or a same-day regimen in the case of afternoon colonoscopy) for routine bowel preparation. A split regimen (or same-day regimen in the case of afternoon colonoscopy) of 2L PEG plus ascorbate or of sodium picosulphate plus magnesium citrate may be valid alternatives, in particular for elective outpatient colonoscopy (strong recommendation, high quality evidence). In patients with renal failure, PEG is the only recommended bowel preparation. The delay between the last dose of bowel preparation and colonoscopy should be minimized and no longer than 4 hours (strong recommendation, moderate quality evidence). (3) The ESGE advises against the routine use of sodium phosphate for bowel preparation because of safety concerns (strong recommendation, low quality evidence).

TF1

Non-laxative measures

Statement #1

**The ESGE recommends a low-fiber diet on the day preceding colonoscopy
(weak recommendation, moderate quality evidence).**

**The ESGE does not make any recommendations regarding the use of low-fiber diet for more than 24 hours prior to the examination
(insufficient evidence to make a recommendation).**

Statement #1: Rationale

- Efficacy of dietary modifications supported only by poorly controlled pre-PEG data (i.e. radiological)
- Dietary modifications included in most of PEG-based studies, leaving uncertainty on their exclusion
- RCT with bias showed a superiority of low-fiber diet over liquid diet, in the efficacy (1 of 2 RCT) or in the tolerability (2 of 2 RCT)

| Study | Patient N° | Comparison | Outcome |
|---------|------------|--|-------------------------------|
| Delegge | 506 | Low-fiber+MgCi vs liquid diet with NaP | Low-fiber+MgCi more effective |

Statement #2: Rationale

- Some centers prescribe low-fiber diet for 3 days because some patients have slow transit time; no evidence is available to recommend 1 or 3 days

Statement #3

The ESGE recommends against the routine use of enemas in addition to oral bowel preparation (strong recommendation, moderate quality evidence).

Statement #3: Rationale

- Two RCT showed the **lack of any benefit** in adding enemas to oral BP.
- The addition of **enemas** reduced the **acceptability** of BP.

Statement #3: Rationale


| Study | Patient N° | Comparison | Outcome |
|--------|------------|--------------------------------------|--|
| Lever* | 82 | Oral lavage vs oral lavage+enemas | Cleanliness equal Pts would refuse further prep: 12% vs 22% |
| Borkje | 271 | Oral senna+enema vs PEG vs Picosalax | PEG superior |

Statement #4-5

The ESGE recommends adding simethicone to standard bowel preparation (weak recommendation, high quality evidence).

The ESGE does not recommend the routine use of prokinetic agents as adjunct to bowel preparation (weak recommendation, moderate quality evidence).

Systematic review



Simeticone has been shown to significantly decrease air bubbles at colonoscopy (OR = 39.32, 95% CI: 11.38–135.86, $p = 0.00$), with no significant heterogeneity ($p = 0.29$, $I^2 = 20.0\%$).

Wu L et al. Scand J Gastroenterol 2011;46(2):227-35

TF2/TF5

PEG/Mg Ci

Statement #6

The ESGE recommends a split regimen of 4-L PEG solution (or same-day in the case of afternoon colonoscopy) for routine bowel preparation. A split (or same-day in the case of afternoon colonoscopy) regimen of 2-L PEG plus ascorbate or of sodium picosulphate/magnesium citrate may be valid alternatives, in particular for elective outpatient colonoscopy.

(strong recommendation, high quality evidence).

In patients with renal failure, PEG is the single recommended bowel preparation. The delay between the last dose of bowel preparation and colonoscopy should be minimized and no longer than 4 hours

(strong recommendation, moderate quality evidence).

Statement #6:PEG Rationale

- 5 meta-analysis showed comparable or lower efficacy of PEG vs NaP, as well as comparable efficacy with Mg Ci/SPS.

Statement #6: Rationale

| Author | Study | Intervention | Conclusions |
|----------|--------|---|---|
| Hsu CW | 8 RCT | 2x45mL NaP vs. 4L PEG | Equivalence for adequate; NaP superior for excellent |
| Tan JJY, | 29 RCT | 2x45mL NaP vs. 3-4L PEG vs. 10-30mg SPS | PEG less efficacious than NaP and equal to SPS |
| Belsey | 82 RCT | 2x45mL or 90mL NaP solution or NaP tablets vs. 3-4L PEG | Equivalence |
| Juluri R | 18 RCT | 2x45mL NaP vs. 4L PEG | NaP more effective |
| Juluri R | 71 RCT | 4L PEG alone +/- adjunctive medications, 2L PEG + adjunctive medication, split-dose PEG (2L+2L or 2L+1L), 2x45mL NaP solution +/- adjunctive medications, NaP tablets | NaP tablets superior to PEG |

Statement #6: Split- Rationale

- 18 RCT (3256 pts. split , 2919 non-split), including PEG (high or low dose) and NaP or Mg Ci
- Pooling of data independently of the type of comparison shows an improved degree of bowel cleansing good/excellent of 20% [95% CI 0.14 - 0.26], ($p < .0000$, I^2 91.1%) favoring the split regimen.
- In 23 out of the 24 comparisons the split schedule provided the best degree of bowel cleansing.

Statement #6: Rationale

| Comparison | N. pts. | Rate difference (95% CI) | P< | I ² |
|--------------------------------------|---------|----------------------------|-------|----------------|
| Peg low vs Peg low | 917 | 0.180 (0.014- 0.346) | 0.034 | 91.2% |
| Fosfo vs Fosfo | 1519 | 0.244 (0.108 - 0.380) | 0.000 | 92.9% |
| *Peg High vs Peg Low | 172 | 0.04 (-0.042 - 0.131) | .314 | . |
| Peg Hi vs Peg High | 1305 | 0.306 (0.192 - 0.421) | 0.000 | 81.5% |
| *Peg Hi vs sodium citrate+Peg Low | 152 | 0.247 (0.099 - 0.395) | 0.001 | . |
| Fosfo soda vs Peg High | 1021 | 0.136 (0.067 - 0.204) | 0.000 | 67.9% |
| Fosfo soda vs Peg Low | 652 | 0.155 (0.098- 0.212) | 0.000 | 0.0% |
| Pospho soda vs Mg citrate | 437 | -0.094 (-0.150 to -0.038) | 0.001 | . |

Statement #6: delay-Rationale

| Time (hours) to colonoscopy | N. comparison | N. pts. | Rate difference (95% CI) | P= | I ² |
|-----------------------------|---------------|---------|--------------------------|-------|----------------|
| 1.3 | 1 | 141 | 0.203 (0.051 - 0.355) | 0.009 | . |
| 2 Hours | 11 | 3120 | 0.293 (0.200- 0.387) | 0.000 | 92.9% |
| 3 hours | 8 | 1051 | 0.137 (0.082 - 0.193) | 0.000 | 44.9% |
| 4 hours | 2 | 894 | 0.009 (-0.198 to 0.217) | 0.929 | 94.5% |
| 6 hours | 1 | 107 | 0.032 (-0.078 to 0.142) | 0.565 | . |

Statement #6: low-volume Rationale

- Overall, 11 studies, including over 7,000 randomized subjects, have generally shown a similar efficacy between high- and low-volume PEG regimens.
- As expected, low-volume PEG preparation were not associated with a higher rate of adverse events as compared with the high-volume PEG regimens, whilst it was generally associated with a better tolerability.

Statement #6:Low-PEG Rationale

| | | | | | |
|-----------|------|-------------------------------------|-------------------|---------------------------|-------|
| Cohen | 216 | peg 2l+asc vs peg 2l+bys | peg asc better | equal | mono |
| Ell | 359 | peg 2l+asc vs 4l | equal | peg 2l better | multi |
| Corporaal | 350 | 2 l asc acidvs 4l | equally | equal | mono |
| Marmo | 1763 | peg 2l asc acid vs 4l | equal | more palatable | multi |
| Bitoun | 352 | 2l+asc vs nap | equal | more tolerable | mono |
| Hookey | 2688 | peg 2l+sennosides vs 4l | 4 peg better | 2 l more better tolerated | mono |
| Di Palma | 200 | peg 2l sulfate free+ bys vs 4-l peg | equal | 2 l better tolerated | multi |
| Ker | 912 | nap vs 2l+bys vs 4l | equal | worse for 4l | mono |
| Ker | 300 | 2l + bys vs 4l | equal | better with 2 l | mono |
| Adams | 382 | 2l + bys vs 4l | equal | better with 2l | mono |
| Park | 232 | 2l+mag vs 4l | 2l more efficient | more tolerable | mono |
| Sharma | 150 | peg 2l+mag citrate or bys vs 4l peg | equal | 2l better tolerated | mono |

Statement #6:Low-Mg/SPS Rationale

| Author | Regime | Pt no | Cleansing | Tolerability |
|---------------|---|-------|----------------|--|
| Berkel-hammer | NaP 45ml vs Mg 300ml | 300 | Mg>NaP overall | NaP > Mg |
| Schmidt | NaP 90 ml vs Mg & SPS | 400 | Equal | Mg>NaP |
| Tjandra | NaP 90 ml vs Mg & SPS | 225 | NaP>Mg | Mg> |
| Yoshioka | NaP 90 ml vs Mg & SPS | 103 | NaP>Mg | NSD |
| Hamilton | 4l PEG vs Mg & SPS | 69 | Equal | Mg & SPS>PEG |
| Renaut | NaP vs Mg & SPS | 73 | Equal | Mg & SPS>NaP |
| Rapier | PEG with clear liquid diet vs Mg & bisacodyl with low residue or clear liquid diet. | 114 | Equal | Equal |
| Regev | PEG 3l vs Mg & SPS | 68 | Mg>PEG | Mg & SPS>PEG |
| Worthington | PEG & ascorbic acid vs Mg & SPS | 65 | PEG > Mg | Mg & SPS>PEG & ascorbic acid (p<0.001) |

Statement #7-8

The ESGE advises against the routine use of oral sodium phosphate for bowel preparation because of safety concerns.

(strong recommendation, low quality evidence)

The ESGE suggests that oral sodium phosphate can only be advised in selected cases of specific needs that cannot be met by alternative products (e.g., patient unable to tolerate other agents) and only in subjects assessed by physicians to be at low risk of oral sodium phosphate-related side-effects. An evaluation of the kidney function should be available before prescribing oral sodium phosphate.

(weak recommendation, low quality evidence).

If oral sodium phosphate is used for bowel preparation, 90 mL (solution) or 32 tablets containing 1.5 gram NaP each in split-dose regimen is recommended.

(strong recommendation, high quality evidence).

Statement #7: Rationale

- Systematic review serious AE (n=109) (Belsey 2009)
 - (i) Electrolyte imbalance (n=46, 11 deaths)
 - (ii) **delayed renal failure** (APN, n=26);
 - (iii) colon aphthous ulcerations (n=37)
- Meta-analysis of 7 controlled trials (n=12,168) comparing kidney function after OSP vs. other BP: no significant association (Brunelli 2009).
- **Over a 2-year period, 171 cases of renal failure were reported to the FDA following the use of OSP and 10 following the use of PEG -> FDA warning.**
- A population-based national Icelandic retrospective analysis: biopsy-proven APN in 1/1000 sold doses of OSP (Pálmadóttir 2010).

Statement #8: Rationale

- **Risk factors** include age **>55 years**, hypovolemia, baseline kidney disease, bowel obstruction or active colitis, drugs affecting renal perfusion or function such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and NSAIDs.
- Recommendations to prevent AE (Balaban 2008):
 - **Proper dosing and hydration**
 - **Adequate patient instructions** (prescriber should ensure patient understanding)

Statement #9

In patients with inadequate bowel cleansing, the ESGE suggests the adoption of endoscopic irrigation pumps or repeating colonoscopy on the following day after additional bowel preparation (weak recommendation, low quality evidence).

For the first colonoscopy, the use of models to identify patients at increased risk of inadequate cleansing with the aim to adapt the bowel preparation is not recommended. (insufficient evidence to determine net benefits or risks)

Statement #9: Rationale

- Five studies including (20,000 patients) showed increased age, male sex, in-patient status and comorbidities to predict inadequate preparation.
- Sociodemographic variables – such as literacy and marital status – also resulted to be associated with an unfavourable outcome.
- No evidence on the efficacy of alternative regimens in those at higher risk of inadequate preparation.

Statement #9: Rationale

| Author | Pts. | BP | Predictive factors |
|---------|-------|----------------|---|
| Borg | 1815 | PEG/NAP | Demographic, indication, inpatient, medical hx,race, weight, height, comorbid., drugs, alcohol, tobacco |
| Ness | 732 | PEG/NAP | Demographic, indication, inpatient, medical hx,race, weight, height, comorbid., drugs, regimen, compliance, bmi frequency, prevoius surgery |
| Chan | 522 | PEG 2L | Demographics, bmi, in-pt, timing oc, indication,hx med, hx oc, prev surger, compliance bp |
| Lebwohl | 13498 | PEG | demogr, in-pt, time oc, marital status, medicaid status |
| Hassan | 2811 | PEG/PEG 2l/NaP | demographic data, indication and comorbidities |
| Chung | 362 | PEG | Age, comorbidity, surgery |

Conclusions

- 1-day low-fiber diet – new studies needed
- Simethicone highly effective in reducing bubbles - new studies on ADR needed
- 4 Liter as first-choice – Low-volume PEG/PSP as valid alternatives
- Split essential to close the interval between BP and colonoscopy